396 related articles for article (PubMed ID: 25714506)
1. Cost-effectiveness of quadrivalent influenza vaccine in Hong Kong - A decision analysis.
You JH; Ming WK; Chan PK
Hum Vaccin Immunother; 2015; 11(3):564-71. PubMed ID: 25714506
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness analysis of quadrivalent influenza vaccine versus trivalent influenza vaccine for elderly in Hong Kong.
You JH; Ming WK; Chan PK
BMC Infect Dis; 2014 Nov; 14():618. PubMed ID: 25420713
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness analysis of quadrivalent versus trivalent influenza vaccine in Taiwan: A lifetime multi-cohort model.
Yang MC; Tan EC; Su JJ
Hum Vaccin Immunother; 2017 Jan; 13(1):81-89. PubMed ID: 27624648
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness analysis of quadrivalent influenza vaccine in Spain.
García A; Ortiz de Lejarazu R; Reina J; Callejo D; Cuervo J; Morano Larragueta R
Hum Vaccin Immunother; 2016 Sep; 12(9):2269-77. PubMed ID: 27184622
[TBL] [Abstract][Full Text] [Related]
5. Cost-Effectiveness of Quadrivalent versus Trivalent Influenza Vaccine in the United States.
de Boer PT; Crépey P; Pitman RJ; Macabeo B; Chit A; Postma MJ
Value Health; 2016 Dec; 19(8):964-975. PubMed ID: 27987647
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of quadrivalent versus trivalent influenza vaccine for elderly population in China.
Jiang M; Li P; Wang W; Zhao M; Atif N; Zhu S; Fang Y
Vaccine; 2020 Jan; 38(5):1057-1064. PubMed ID: 31787414
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness evaluation of quadrivalent influenza vaccines for seasonal influenza prevention: a dynamic modeling study of Canada and the United Kingdom.
Thommes EW; Ismaila A; Chit A; Meier G; Bauch CT
BMC Infect Dis; 2015 Oct; 15():465. PubMed ID: 26503131
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness analysis of quadrivalent influenza vaccination in at-risk adults and the elderly: an updated analysis in the U.K.
Meier G; Gregg M; Poulsen Nautrup B
J Med Econ; 2015; 18(9):746-61. PubMed ID: 25903831
[TBL] [Abstract][Full Text] [Related]
9. Cost Effectiveness of Quadrivalent Influenza Vaccines Compared with Trivalent Influenza Vaccines in Young Children and Older Adults in Korea.
Kim YK; Song JY; Jang H; Kim TH; Koo H; Varghese L; Han E
Pharmacoeconomics; 2018 Dec; 36(12):1475-1490. PubMed ID: 30251078
[TBL] [Abstract][Full Text] [Related]
10. Cost-Utility of Quadrivalent Versus Trivalent Influenza Vaccine in Germany, Using an Individual-Based Dynamic Transmission Model.
Dolk C; Eichner M; Welte R; Anastassopoulou A; Van Bellinghen LA; Poulsen Nautrup B; Van Vlaenderen I; Schmidt-Ott R; Schwehm M; Postma M
Pharmacoeconomics; 2016 Dec; 34(12):1299-1308. PubMed ID: 27647004
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of switching from trivalent to quadrivalent inactivated influenza vaccines for the at-risk population in Italy.
Mennini FS; Bini C; Marcellusi A; Rinaldi A; Franco E
Hum Vaccin Immunother; 2018; 14(8):1867-1873. PubMed ID: 29708843
[TBL] [Abstract][Full Text] [Related]
12. From trivalent to quadrivalent influenza vaccines: Public health and economic burden for different immunization strategies in Spain.
Crépey P; Redondo E; Díez-Domingo J; Ortiz de Lejarazu R; Martinón-Torres F; Gil de Miguel Á; López-Belmonte JL; Alvarez FP; Bricout H; Solozabal M
PLoS One; 2020; 15(5):e0233526. PubMed ID: 32437476
[TBL] [Abstract][Full Text] [Related]
13. Impact of quadrivalent influenza vaccine on public health and influenza-related costs in Australia.
Jamotte A; Chong CF; Manton A; Macabeo B; Toumi M
BMC Public Health; 2016 Jul; 16():630. PubMed ID: 27449665
[TBL] [Abstract][Full Text] [Related]
14. Impact of quadrivalent influenza vaccines in Brazil: a cost-effectiveness analysis using an influenza transmission model.
Crépey P; Boiron L; Araujo RR; Lopez JG; Petitjean A; de Albuquerque Luna EJ
BMC Public Health; 2020 Sep; 20(1):1374. PubMed ID: 32907562
[TBL] [Abstract][Full Text] [Related]
15. [Cost-effectiveness analysis of quadrivalent influenza vaccination for older adults aged 60 and above in mainland China].
Yan H; Yang J; Chen ZY; Gong H; Zhong GJ; Yu HJ
Zhonghua Yi Xue Za Zhi; 2021 Aug; 101(30):2405-2412. PubMed ID: 34404135
[No Abstract] [Full Text] [Related]
16. Cost-Effectiveness of Quadrivalent Versus Trivalent Influenza Vaccination in the Dutch National Influenza Prevention Program.
Zeevat F; Crépey P; Dolk FCK; Postma AJ; Breeveld-Dwarkasing VNA; Postma MJ
Value Health; 2021 Jan; 24(1):3-10. PubMed ID: 33431150
[TBL] [Abstract][Full Text] [Related]
17. Safety and immunogenicity of a quadrivalent inactivated influenza vaccine in adults.
Pépin S; Donazzolo Y; Jambrecina A; Salamand C; Saville M
Vaccine; 2013 Nov; 31(47):5572-8. PubMed ID: 24016810
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity and safety of inactivated quadrivalent and trivalent influenza vaccines in children 18-47 months of age.
Rodriguez Weber MA; Claeys C; Aranza Doniz C; Feng Y; Innis BL; Jain VK; Peeters M
Pediatr Infect Dis J; 2014 Dec; 33(12):1262-9. PubMed ID: 25386965
[TBL] [Abstract][Full Text] [Related]
19. Public health impact and economic benefits of quadrivalent influenza vaccine in Latin America.
Jamotte A; Clay E; Macabeo B; Caicedo A; Lopez JG; Bricks L; Romero Prada M; Marrugo R; Alfonso P; Moreno Arévalo B; Franco D; Garcia Diaz L; Isaza de Molto Y
Hum Vaccin Immunother; 2017 Apr; 13(4):877-888. PubMed ID: 28118092
[TBL] [Abstract][Full Text] [Related]
20. Immunogenicity, reactogenicity, and safety of inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine in healthy adults aged ≥18 years: a phase III, randomized trial.
Tinoco JC; Pavia-Ruz N; Cruz-Valdez A; Aranza Doniz C; Chandrasekaran V; Dewé W; Liu A; Innis BL; Jain VK
Vaccine; 2014 Mar; 32(13):1480-7. PubMed ID: 24486352
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]